Bing Xiong

List of Publications by Year
in descending order

101 papers	1,951 citations	279798 23 h-index	330143 37 g-index
111 all docs	111 docs citations	111 times ranked	2843 citing authors

#	Article	IF	Citations
1	Dopamine D₁ receptor ligands: Where are we now and where are we going. Medicinal Research Reviews, 2009, 29, 272-294.	10.5	117
2	Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain. Journal of Medicinal Chemistry, 2013, 56, 3833-3851.	6.4	113
3	Conserved Î±-Helix Acts as Autoinhibitory Sequence in AMP-activated Protein Kinase Î± Subunits. Journal of Biological Chemistry, 2007, 282, 495-506.	3.4	96
4	Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and Î²-secretase. Bioorganic and Medicinal Chemistry, 2009, 17, 1600-1613.	3.0	95
5	Inhibitory Mode of 1,5-Diarylpyrazole Derivatives against Cyclooxygenase-2 and Cyclooxygenase-1:Â Molecular Docking and 3D QSAR Analyses. Journal of Medicinal Chemistry, 2002, 45, 4816-4827.	6.4	61
6	Salvicine Functions as Novel Topoisomerase II Poison by Binding to ATP Pocket. Molecular Pharmacology, 2006, 70, 1593-1601.	2.3	54
7	Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization. Journal of Medicinal Chemistry, 2015, 58, 1281-1297.	6.4	50
8	Brownian Dynamics Simulations of the Recognition of the Scorpion Toxin Maurotoxin with the Voltage-Gated Potassium Ion Channels. Biophysical Journal, 2002, 83, 2370-2385.	0.5	49
9	Design and Optimization of a Series of 1-Sulfonylpyrazolo[4,3-b]pyridines as Selective c-Met Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 2513-2529.	6.4	42
10	Mechanism of the All-Î± to All-Î² Conformational Transition of RfaH-CTD: Molecular Dynamics Simulation and Markov State Model. Journal of Chemical Theory and Computation, 2014, 10, 2255-2264.	5.3	37
11	Structure of the Antibiotic Resistance Factor Spectinomycin Phosphotransferase from Legionella pneumophila. Journal of Biological Chemistry, 2010, 285, 9545-9555.	3.4	36
12	Condensed Fukui function predicts innate Câ€“H radical functionalization sites on multi-nitrogen containing fused arenes. RSC Advances, 2014, 4, 17262-17264.	3.6	35
13	Knowledge-Based Scoring Functions in Drug Design. 1. Developing a Target-Specific Method for Kinaseâ^'Ligand Interactions. Journal of Chemical Information and Modeling, 2010, 50, 1378-1386.	5.4	33
14	Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors. European Journal of Medicinal Chemistry, 2014, 87, 765-781.	5.5	33
15	Knowledge-Based Scoring Functions in Drug Design: 2. Can the Knowledge Base Be Enriched?. Journal of Chemical Information and Modeling, 2011, 51, 386-397.	5.4	31
16	Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Oncotarget, 2017, 8, 4156-4168.	1.8	31
17	Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 8642-8663.	6.4	30
18	Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor. European Journal of Medicinal Chemistry, 2017, 137, 176-195.	5.5	28

#	Article	IF	Citations
19	BSSF: a fingerprint based ultrafast binding site similarity search and function analysis server. BMC Bioinformatics, 2010, 11, 47.	2.6	27
20	Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives. Acta Pharmacologica Sinica, 2006, 27, 1259-1271.	6.1	26
21	Water PMF for predicting the properties of water molecules in protein binding site. Journal of Computational Chemistry, 2013, 34, 583-592.	3.3	25
22	MT119, a new planarâ€structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation. International Journal of Cancer, 2011, 129, 214-224.	5.1	24
23	Virtual Screening and Structure-Based Discovery of Indole Acylguanidines as Potent Î²-secretase (BACE1) Inhibitors. Molecules, 2013, 18, 5706-5722.	3.8	24
24	Direct Glycosylation of Bioactive Small Molecules with Glycosyl Iodide and Strained Olefin as Acid Scavenger. Journal of Organic Chemistry, 2014, 79, 1100-1110.	3.2	24
25	Structures of aminoglycoside acetyltransferase AAC(6â€²)-Ii in a novel crystal form: structural and normal-mode analyses. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 1273-1279.	2.5	23
26	Illudalic acid as a potential LAR inhibitor: Synthesis, SAR, and preliminary studies on the mechanism of action. Bioorganic and Medicinal Chemistry, 2008, 16, 7399-7409.	3.0	23
27	Crystal Structures of Two Aminoglycoside Kinases Bound with a Eukaryotic Protein Kinase Inhibitor. PLoS ONE, 2011, 6, e19589.	2.5	23
28	MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules. Investigational New Drugs, 2010, 28, 715-728.	2.6	22
29	Structural Analysis of a Novel Cyclohexylamine Oxidase from Brevibacterium oxydans IH-35A. PLoS ONE, 2013, 8, e60072.	2.5	22
30	Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors. Acta Pharmacologica Sinica, 2016, 37, 698-707.	6.1	22
31	Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. Molecular Cancer Therapeutics, 2018, 17, 751-762.	4.1	22
32	Discovery of pyrazole as C-terminus of selective BACE1 inhibitors. European Journal of Medicinal Chemistry, 2013, 68, 270-283.	5.5	20
33	Multi-substituted 8-aminoimidazo[1,2-a]pyrazines by Groebkeâ€“Blackburnâ€“BienaymÃ© reaction and their Hsp90 inhibitory activity. Organic and Biomolecular Chemistry, 2015, 13, 1531-1535.	2.8	20
34	Fragment-based drug discovery of triazole inhibitors to block PDEÎ´-RAS protein-protein interaction. European Journal of Medicinal Chemistry, 2019, 163, 597-609.	5.5	20
35	ScafBank: a public comprehensive Scaffold database to support molecular hopping. Acta Pharmacologica Sinica, 2009, 30, 251-258.	6.1	19
36	Strained olefin enables triflic anhydride mediated direct dehydrative glycosylation. Organic and Biomolecular Chemistry, 2014, 12, 9781-9785.	2.8	19

#	Article	IF	Citations
37	Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer. Acta Pharmaceutica Sinica B, 2016, 6, 93-99.	12.0	18
38	Knowledge-Based Scoring Functions in Drug Design: 3. A Two-Dimensional Knowledge-Based Hydrogen-Bonding Potential for the Prediction of Proteinâ€“Ligand Interactions. Journal of Chemical Information and Modeling, 2011, 51, 2994-3004.	5.4	17
39	NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds. Acta Pharmacologica Sinica, 2016, 37, 984-993.	6.1	17
40	Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 721-725.	2.2	17
41	Highly Stereoselective Nucleophilic Addition of Difluoromethylâ€2â€pyridyl Sulfone to Sugar Lactones and Efficient Synthesis of Fluorinated 2â€Ketoses. European Journal of Organic Chemistry, 2014, 2014, 6150-6154.	2.4	16
42	Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2525-2529.	2.2	16
43	Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. European Journal of Medicinal Chemistry, 2018, 150, 156-175.	5.5	16
44	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. European Journal of Medicinal Chemistry, 2010, 45, 1133-1139.	5.5	15
45	Structure of SARS-CoV-2 main protease in the apo state. Science China Life Sciences, 2021, 64, 656-659.	4.9	15
46	Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy. Journal of Medicinal Chemistry, 2021, 64, 16650-16674.	6.4	15
47	Quinoxalinylurea derivatives as a novel class of JSP-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2118-2122.	2.2	14
48	DrugViz: a Cytoscape plugin for visualizing and analyzing small molecule drugs in biological networks. Bioinformatics, 2008, 24, 2117-2118.	4.1	14
49	Potent and novel 11Î²-HSD1 inhibitors identified from shape and docking based virtual screening. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5739-5744.	2.2	14
50	Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l-kynurenine. Cell Death and Disease, 2019, 10, 557.	6.3	14
51	CCLabâ€”a multi-objective genetic algorithm based combinatorial library design software and an application for histone deacetylase inhibitor design. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4540-4545.	2.2	13
52	Design, synthesis and SAR of piperidyl-oxadiazoles asÂ11Î²-hydroxysteroid dehydrogenase 1 inhibitors. European Journal of Medicinal Chemistry, 2013, 62, 1-10.	5.5	13
53	Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2019, 62, 5414-5433.	6.4	13
54	The type IA topoisomerase catalytic cycle: A normal mode analysis and molecular dynamics simulation. Proteins: Structure, Function and Bioinformatics, 2008, 71, 1984-1994.	2.6	12

#	Article	IF	Citations
55	Aromatic Î²-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists. Bioorganic and Medicinal Chemistry, 2010, 18, 4255-4268.	3.0	12
56	Discovery of 3Hâ€imidazo[4,5â€b]pyridines as Potent câ€Met Kinase Inhibitors: Design, Synthesis, and Biological Evaluation. ChemMedChem, 2012, 7, 1057-1070.	3.2	12
57	Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11Î²-hydroxysteroid dehydrogenase type 1. Molecular and Cellular Endocrinology, 2012, 358, 46-52.	3.2	12
58	Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. European Journal of Medicinal Chemistry, 2019, 163, 671-689.	5.5	12
59	Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases. Journal of Medicinal Chemistry, 2020, 63, 9787-9802.	6.4	12
60	Discovery of 2-Alkyl-1-arylsulfonylprolinamides as 11Î²-Hydroxysteroid Dehydrogenase Type 1 Inhibitors. ACS Medicinal Chemistry Letters, 2012, 3, 793-798.	2.8	11
61	Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors. Molecules, 2018, 23, 698.	3.8	11
62	Construction of a small peptide library related to inhibitor OM99-2 and its structure-activity relationship to ?-secretase. Acta Pharmacologica Sinica, 2006, 27, 1586-1593.	6.1	10
63	Design and Synthesis of 4â€(2,4,5â€Trifluorophenyl)butaneâ€1,3â€diamines as Dipeptidyl Peptidaseâ€…IV Inhibitors. ChemMedChem, 2013, 8, 1104-1116.	3.2	10
64	Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors. Molecules, 2016, 21, 1407.	3.8	10
65	Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 844-847.	2.2	10
66	Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 9459-9477.	6.4	10
67	Sulfated polymannuroguluronate inhibits Tat-induced SLK cell adhesion via a novel binding site, a KKR spatial triad. Acta Pharmacologica Sinica, 2011, 32, 647-654.	6.1	9
68	Design and synthesis of benzylpiperidine inhibitors targeting the meninâ€“MLL1 interface. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4472-4476.	2.2	9
69	1,2-trans-1-Dihydroxyboryl benzyl S-glycoside as glycosyl donor. Carbohydrate Research, 2014, 398, 45-49.	2.3	8
70	Preparation of 5â€²-deoxy-5â€²-amino-5â€²-C-methyl adenosine derivatives and their activity against DOT1L. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4960-4963.	2.2	8
71	Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors. Molecules, 2017, 22, 583.	3.8	8
72	Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors. Bioorganic and Medicinal Chemistry Letters, 2021, 33, 127749.	2.2	8

#	Article	IF	Citations
73	Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1. Biochemical Pharmacology, 2021, 185, 114435.	4.4	8
74	Formation of 1,3-diazocine by palladium catalyzed Câ€“H arylation. Tetrahedron Letters, 2016, 57, 2311-2314.	1.4	7
75	Design and optimization of purine derivatives as in vivo active PDE10A inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3315-3329.	3.0	7
76	Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis. Acta Pharmacologica Sinica, 2022, 43, 1769-1779.	6.1	7
77	Discovery of potent Î²-secretase (bace-1) inhibitors by the synthesis of isophthalamide-containing hybrids. Acta Pharmacologica Sinica, 2009, 30, 259-269.	6.1	6
78	Design and Synthesis of (R)â€1â€Arylsulfonylpiperidineâ€2â€carboxamides as 11Î²â€Hydroxysteroid Dehydrogenase Typeâ€…1 Inhibitors. ChemMedChem, 2013, 8, 577-581.	3.2	6
79	Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. Investigational New Drugs, 2021, 39, 1213-1221.	2.6	6
80	The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation. Molecular Cancer Therapeutics, 2021, 20, 2198-2206.	4.1	6
81	FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells. Oncoscience, 2015, 2, 419-427.	2.2	6
82	Energetic factors determining the binding of type I inhibitors to c-Met kinase: experimental studies and quantum mechanical calculations. Acta Pharmacologica Sinica, 2013, 34, 1475-1483.	6.1	5
83	Efficient syntheses of alpha- and beta-C-nucleosides and the origin of anomeric selectivity. Organic Chemistry Frontiers, 2018, 5, 1992-1999.	4.5	5
84	Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structureâ€“activity relationship, crystal structural characterization and in vivo study. Acta Pharmaceutica Sinica B, 2019, 9, 351-368.	12.0	5
85	Crystallization and preliminary crystallographic analysis of an aminoglycoside kinase fromLegionella pneumophila. Acta Crystallographica Section F: Structural Biology Communications, 2005, 61, 606-608.	0.7	4
86	Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells. Acta Pharmacologica Sinica, 2016, 37, 1587-1596.	6.1	4
87	Stereoselective addition of Grignard reagents to (2-methyl-5-tert-butyl)phenyl 1-thio-Î²-D-ribopentodialdo-1,4-furanoside derivative. Tetrahedron, 2017, 73, 2290-2304.	1.9	4
88	A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction. Investigational New Drugs, 2020, 38, 700-713.	2.6	4
89	EPHA2 feedback activation limits the response to PDEÎ´ inhibition in KRAS-dependent cancer cells. Acta Pharmacologica Sinica, 2020, 41, 270-277.	6.1	4
90	Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5. Molecules, 2021, 26, 1225.	3.8	4

#	Article	IF	Citations
91	Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells. Genomics, 2021, 113, 1057-1069.	2.9	4
92	Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino)) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 712 Td (quinazolin-6-yl)-N- inhibitors for the treatment of idiopathic pulmonary fibrosis. Acta Pharmaceutica Sinica B, 2022, 12, 1943-1962.	12.0	4
93	Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities. European Journal of Medicinal Chemistry, 2022, 239, 114519.	5.5	4
94	Stereoselective and Regioselective Preparation of Câ€Pentopyranosides and Formal Synthesis of Omarigliptin. European Journal of Organic Chemistry, 2016, 2016, 5624-5628.	2.4	3
95	Stereoselective N-glycosylation with N4-acyl cytosines and efficient synthesis of gemcitabine. Tetrahedron, 2019, 75, 1203-1213.	1.9	2
96	Allosteric Modulation: Dynamics is Double-â€œEâ€dged. Journal of Medicinal Chemistry, 2021, 64, 3694-3696.	6.4	2
97	Convenient preparation of pinometostat and related 5â€²-deoxy-5â€²-amino adenosine derivatives as well as their activity against DOT1L. Tetrahedron Letters, 2018, 59, 415-417.	1.4	1
98	Divalent tranylcypromine derivative as lysine-specific demethylase 1 inhibitor. Medicinal Chemistry Research, 2021, 30, 421-428.	2.4	1
99	Back Cover: Discovery of 3H-Imidazo[4,5-b]pyridines as Potent c-Met Kinase Inhibitors: Design, Synthesis, and Biological Evaluation (ChemMedChem 6/2012). ChemMedChem, 2012, 7, 1129-1129.	3.2	0
100	A one-pot synthesis of omarigliptin and its analogues through stabilized beta-amino ketone intermediate. Synthetic Communications, 2017, 47, 357-363.	2.1	0
101	Fragment-Based Drug Discovery for Developing Inhibitors of Protein-Protein Interactions. , 2018, , 135-176.		0